Miguel TovarFlipboardIcon version of the Flipboard logoNovartis' migraine drug gets EMA approvalpharmatimes.comAimovig becomes Europe’s first treatment specifically designed to prevent migraine
Miguel TovarPfizer CEO on what happened after Trump tweetedverified_publisherCNBC - Meg TirrellBefore he even spoke to the president, Pfizer CEO Ian Read said he knew the best move was to defer the drug giant's early July price increases; a …
Miguel TovarKyoto team pits iPS cells against Parkinson's diseasejapantimes.co.jp - No AuthorA Kyoto University research team said Monday it will begin a clinical test this week using induced pluripotent stem cells to treat Parkinson’s …
Miguel TovarHighly Anticipated Data On Would-Be Alzheimer's Drug Raises Hope And QuestionsForbes - Ellie KincaidHow does Biogen Chief Medical Officer Al Sandrock feel after the curtain was lifted on clinical trial data of the experimental Alzheimer’s drug his company is developing with Japanese drugmaker Eisai? “It was a shot in the arm for me,” he says of the trial results, which showed BAN-2401 cleared …
Miguel TovarGSK bets $300 million on genetics as CEO plays down break-up talkverified_publisherReuters - Ben HirschlerLONDON (Reuters) - GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a source of cash generation for such R&D investment. GSK is buying a $300 million stake in the Silicon …
Miguel TovarEisai, Biogen battered by controversy over PhII Alzheimer's study after posting positive resultsendpts.com - John CarrollAt first blush, Eisai and Biogen posted the kind of promising data for BAN2401 that might have overcome some doubts about its potential as a …
